Skip to main content

Dr. Robert T. Naismith, MD

Neurology (Neurology Physician)

  • Medicare participating

At a glance

Years since graduation
28
In the NPI registry since
2006
Medicare patients seen, 2024
79

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neurology Physician primary
    MO license 2000146127

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Neurology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
79
Services billed
143
Patients’ average age
64
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes3933
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes2120
Established patient office or other outpatient visit, 10-19 minutes1212

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Gabapentin
Other prescribers in Saint Louis, MO
124
Baclofen
Other prescribers in Saint Louis, MO
91
Kesimpta Pen (ofatumumab)54
Teriflunomide52
Amitriptyline Hcl
Other prescribers in Saint Louis, MO
48
Trazodone Hcl
Other prescribers in Saint Louis, MO
43
Fingolimod (fingolimod hcl)39
Pregabalin
Other prescribers in Saint Louis, MO
32
Dalfampridine Er (dalfampridine)31
Myrbetriq (mirabegron)
Other prescribers in Saint Louis, MO
29

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 13 companies reported 67 payments worth $145,927 in total to this clinician.

By type
Consulting Fee$92,994
Compensation for services other than consulting (speaking, faculty)$45,161
Travel and Lodging$6,224
Food and Beverage$1,549

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 29, 2025Genzyme Corporation
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)$11,074
Dec 11, 2025Genzyme Corporation
Dec 11, 2025
Compensation for services other than consulting (speaking, faculty)$11,074
Apr 23, 2025Genzyme Corporation
Apr 23, 2025
Compensation for services other than consulting (speaking, faculty)$10,808
Oct 15, 2025Sanofi-aventis U.S. LLC
Oct 15, 2025
Consulting Fee$10,500
Nov 15, 2025Sanofi-aventis U.S. LLC
Nov 15, 2025
Consulting Fee$10,500
Mar 12, 2025Sanofi-aventis U.S. LLC
Mar 12, 2025
Consulting Fee$9,600
Sep 15, 2025Sanofi-aventis U.S. LLC
Sep 15, 2025
Consulting Fee$8,850
Jul 15, 2025Sanofi-aventis U.S. LLC
Jul 15, 2025
Consulting Fee$7,050
Dec 15, 2025Sanofi-aventis U.S. LLC
Dec 15, 2025
Consulting Fee$6,600
Sep 2, 2025E.r. Squibb & Sons, L.l.c.
Sep 2, 2025
Consulting Fee$5,038
All 50 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 15, 2025Sanofi-aventis U.S. LLC
Dec 15, 2025
Consulting Fee$6,600
Dec 15, 2025Sanofi-aventis U.S. LLC
Dec 15, 2025
Consulting Fee$1,350
Dec 11, 2025Genzyme Corporation
Dec 11, 2025
Compensation for services other than consulting (speaking, faculty)$11,074
Dec 11, 2025Genzyme Corporation
Dec 11, 2025
Travel and Lodging
travel to Aurora, CO
$669
Dec 11, 2025Genzyme Corporation
Dec 11, 2025
Travel and Lodging
travel to Aurora, CO
$176
Dec 5, 2025AstraZeneca Pharmaceuticals LP
Dec 5, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$2,331
Nov 20, 2025Amgen Inc.
Nov 20, 2025
Compensation for services other than consulting (speaking, faculty)$3,300
Nov 15, 2025Sanofi-aventis U.S. LLC
Nov 15, 2025
Consulting Fee$10,500
Nov 15, 2025Sanofi-aventis U.S. LLC
Nov 15, 2025
Consulting Fee$1,350
Nov 15, 2025Genzyme Corporation
Nov 15, 2025
Consulting Fee$137
Oct 29, 2025Genzyme Corporation
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)$11,074
Oct 29, 2025Genzyme Corporation
Oct 29, 2025
Travel and Lodging
travel to Milwaukee, WI
$661
Oct 29, 2025Genzyme Corporation
Oct 29, 2025
Travel and Lodging
travel to Milwaukee, WI
$202
Oct 15, 2025Sanofi-aventis U.S. LLC
Oct 15, 2025
Consulting Fee$10,500
Oct 15, 2025Sanofi-aventis U.S. LLC
Oct 15, 2025
Consulting Fee$1,350
Oct 15, 2025Genzyme Corporation
Oct 15, 2025
Consulting Fee$546
Sep 30, 2025H. Lundbeck A S
Sep 30, 2025
Compensation for services other than consulting (speaking, faculty)$870
Sep 15, 2025Sanofi-aventis U.S. LLC
Sep 15, 2025
Consulting Fee$8,850
Sep 15, 2025Sanofi-aventis U.S. LLC
Sep 15, 2025
Consulting Fee$1,350
Sep 15, 2025Genzyme Corporation
Sep 15, 2025
Consulting Fee$410
Sep 9, 2025E.r. Squibb & Sons, L.l.c.
Sep 9, 2025
Consulting Fee$1,268
Sep 2, 2025E.r. Squibb & Sons, L.l.c.
Sep 2, 2025
Consulting Fee$5,038
Aug 25, 2025Amgen Inc.
Aug 25, 2025
Compensation for services other than consulting (speaking, faculty)$3,300
Aug 25, 2025Amgen Inc.
Aug 25, 2025
Compensation for services other than consulting (speaking, faculty)$550
Aug 22, 2025Amgen Inc.
Aug 22, 2025
Travel and Lodging
travel to Paducah, KY · in-kind
$713
Aug 15, 2025Sanofi-aventis U.S. LLC
Aug 15, 2025
Consulting Fee$4,950
Aug 15, 2025Sanofi-aventis U.S. LLC
Aug 15, 2025
Consulting Fee$1,050
Aug 11, 2025Celltrion, Inc.
Aug 11, 2025
Consulting Fee$570
Jul 21, 2025Vertex Pharmaceuticals Incorporated
Jul 21, 2025
Consulting Fee$500
Jul 15, 2025Sanofi-aventis U.S. LLC
Jul 15, 2025
Consulting Fee$7,050
Jul 15, 2025Sanofi-aventis U.S. LLC
Jul 15, 2025
Consulting Fee$450
Jun 2, 2025Novartis Pharma AG
Jun 2, 2025
Consulting Fee
Rhapsido · Others
$3,300
May 30, 2025E.r. Squibb & Sons, L.l.c.
May 30, 2025
Travel and Lodging
travel to New Orleans, LA · in-kind
$513
Apr 26, 2025Tg Therapeutics, Inc.
Apr 26, 2025
Compensation for services other than consulting (speaking, faculty)
BRIUMVI · Immunology
$4,185
Apr 26, 2025Tg Therapeutics, Inc.
Apr 26, 2025
Travel and Lodging
BRIUMVI · Immunology · travel to Dallas, TX
$164
Apr 25, 2025Tg Therapeutics, Inc.
Apr 25, 2025
Travel and Lodging
BRIUMVI · Immunology · travel to Dallas, TX · in-kind
$285
Apr 23, 2025Genzyme Corporation
Apr 23, 2025
Compensation for services other than consulting (speaking, faculty)$10,808
Apr 23, 2025Genzyme Corporation
Apr 23, 2025
Travel and Lodging
travel to Fort Collins, CO · in-kind
$827
Apr 23, 2025Genzyme Corporation
Apr 23, 2025
Travel and Lodging
travel to Fort Collins, CO · in-kind
$598
Apr 23, 2025Genzyme Corporation
Apr 23, 2025
Travel and Lodging
travel to Fort Collins, CO
$384
Apr 23, 2025Genzyme Corporation
Apr 23, 2025
Travel and Lodging
travel to Fort Collins, CO
$97.78
Apr 8, 2025E.r. Squibb & Sons, L.l.c.
Apr 8, 2025
Consulting Fee$3,686
Mar 12, 2025Sanofi-aventis U.S. LLC
Mar 12, 2025
Consulting Fee$9,600
Mar 12, 2025Sanofi-aventis U.S. LLC
Mar 12, 2025
Consulting Fee$150
Feb 19, 2025Novartis Pharmaceuticals Corporation
Feb 19, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$572
Feb 19, 2025Novartis Pharmaceuticals Corporation
Feb 19, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$280
Feb 19, 2025Novartis Pharmaceuticals Corporation
Feb 19, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$82.00
Feb 12, 2025Sanofi-aventis U.S. LLC
Feb 12, 2025
Consulting Fee$4,950
Jan 9, 2025Genentech, Inc.
Jan 9, 2025
Consulting Fee$2,760
Jan 8, 2025Sanofi-aventis U.S. LLC
Jan 8, 2025
Consulting Fee$2,400

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 19 industry-funded studies in 2025, from 6 companies. The companies reported $2,304,911 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
    E.r. Squibb & Sons, L.l.c.
  • Satralizumab in MOG AD
    Genentech, Inc.
  • Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE
    F. Hoffmann-la Roche AG
  • A phase iii study to evaluate the efficacy and safety of fenebrutinib in adults with progressive ms
    Genentech, Inc.
  • A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
    Celgene Corporation
  • Ocrelizumab RMS High Dose Study
    Genentech, Inc.
  • An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
    Novartis Pharmaceuticals Corporation
  • Ocrelizumab PPMS High Dose Study
    Genentech, Inc.
  • A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Alexion Pharmaceuticals, Inc.
  • OCARINA I
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Neurology clinicians in Saint Louis

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 17, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1871519090. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.